Signatera™ has received regulatory approval in Japan for use as an adjunctive diagnosis for muscle-invasive bladder cancer
2026-09-22 20:02:56
According to CoinMeta, as reported by Reuters, Signatera™ has received regulatory approval in Japan for use as an adjunctive diagnosis for muscle-invasive bladder cancer.
Bullish 0
Bearish 0
Source:Internet
This content is for market information only and does not constitute investment advice.